Ubs Asset Management Americas Inc Allogene Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 228,806 shares of ALLO stock, worth $519,389. This represents 0.0% of its overall portfolio holdings.

Number of Shares

228,806

Previous 266,784 14.24%

Holding current value

$519,389

Previous $621,000 3.06%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $78,994 - $132,923	-37,978 Reduced 14.24%	228,806 $640,000
Q2 2024 Aug 13, 2024	BUY	$2.23 - $4.38 $215,188 - $422,656	96,497 Added 56.67%	266,784 $621,000
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $39,647 - $76,444	13,578 Added 8.66%	170,287 $761,000
Q3 2023 Nov 13, 2023	SELL	$3.17 - $5.96 $1.19 Million - $2.24 Million	-376,527 Reduced 70.61%	156,709 $496,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $2.62 Million - $4.38 Million	533,236 New	533,236 $2.63 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $824,103 - $1.38 Million	79,855 Added 18.73%	506,137 $5.47 Million
Q2 2022 Aug 12, 2022	BUY	$6.78 - $12.28 $158,821 - $287,659	23,425 Added 5.81%	426,282 $4.86 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $98,646 - $197,164	12,895 Added 3.31%	402,857 $3.67 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $26,535 - $49,554	2,021 Added 0.52%	389,962 $5.82 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $215,121 - $283,005	-10,239 Reduced 2.57%	387,941 $9.97 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $4.06 Million - $6.18 Million	172,689 Added 76.58%	398,180 $10.4 Million
Q1 2021 May 14, 2021	SELL	$25.79 - $39.02 $1 Million - $1.51 Million	-38,814 Reduced 14.69%	225,491 $7.96 Million
Q4 2020 Mar 01, 2021	BUY	$25.24 - $43.45 $99,975 - $172,105	3,961 Added 1.52%	264,305 $6.67 Million
Q3 2020 Nov 13, 2020	BUY	$32.38 - $44.96 $451,150 - $626,427	13,933 Added 5.65%	260,344 $9.82 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $1.17 Million - $3.44 Million	63,727 Added 34.88%	246,411 $10.6 Million
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $394,062 - $610,991	-21,628 Reduced 10.59%	182,684 $3.55 Million
Q4 2019 Feb 14, 2020	BUY	$24.82 - $31.4 $228,989 - $289,696	9,226 Added 4.73%	204,312 $5.31 Million
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $135,275 - $170,921	-5,181 Reduced 2.59%	195,086 $5.32 Million
Q2 2019 Aug 15, 2019	BUY	$25.56 - $31.09 $54,749 - $66,594	2,142 Added 1.08%	200,267 $0
Q1 2019 May 14, 2019	BUY	$24.82 - $32.54 $2.54 Million - $3.33 Million	102,303 Added 106.76%	198,125 $0
Q4 2018 Feb 13, 2019	BUY	$22.5 - $33.3 $2.16 Million - $3.19 Million	95,822 New	95,822 $2.58 Million

Others Institutions Holding ALLO

# of Institutions

162

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Allogene Therapeutics, Inc. Transaction History